Every material Form 8-K Marker Therapeutics, Inc. filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Marker Therapeutics reported third quarter 2025 results on November 14, 2025. The net loss narrowed to $2.0 million from $2.3 million a year earlier, but grant income fell to $1.2 million from $1.9 million, and the nine-month net loss widened to $10.5 million from $6.9 million. The company said its cash will fund operations through the third quarter of 2026, assuming no additional grant funds, after raising approximately $10 million through its ATM facility.
Q3 2025 grant income was $1.2 million, down from $1.9 million in Q3 2024
Q3 2025 net loss was $2.0 million ($0.12 per share), versus $2.3 million ($0.26 per share) a year earlier
Cash and cash equivalents were $17.6 million at September 30, 2025, plus $1.4 million restricted cash
Nine-month net loss was $10.5 million versus $6.9 million, including a $453,135 loss on early termination of a vendor agreement
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Marker Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →